Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy

Helen H.W Chen, Jiang Jou Yan, Wen Chung Chen, Macus Tien Kuo, Yu-Hsuan Lai, Wu-Wei Lai, Hsiao-Sheng Liu, Wu-Chou Su

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Background: Recent studies have shown that human copper transporter 1 (hCtr1), the major copper influx transporter, is involved in the transport of platinum-based antitumor agents. We investigated the predictive and prognostic values of hCtr1, and copper efflux transporters ATP7A and ATP7B, in patients with locally advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-based chemotherapy. Methods: From 2004 to 2009, we identified 54 consecutive stage III NSCLC patients who underwent first-line platinum-based doublet chemotherapy. Immunohistochemical studies of hCtr1, ATP7A and ATP7B on the paraffin-embedded pre-treatment tumor samples were performed and correlated with chemotherapy response and survival. Results: Overexpression of hCtr1, ATP7A and ATP7B were observed in 68%, 48% and 74% of the participants, respectively. hCtr1 overexpression was associated with better chemotherapy responses (P< 0.01); whereas ATP7A and ATP7B were not. Patients with hCtr1 overexpressing tumors had better progression-free survival (PFS) and overall survival (OS) (P= 0.01 and 0.047, respectively). In multivariate analyses for chemotherapy response and PFS, only hCtr1 overexpression emerged as a favorable independent predictive and prognostic factor (all P< 0.01). Conclusion: This is the first report to state that hCtr1 is not only an independent predictor of platinum-based chemotherapy response but also a prognostic factor in stage III NSCLC.

Original languageEnglish
Pages (from-to)228-234
Number of pages7
JournalLung Cancer
Volume75
Issue number2
DOIs
Publication statusPublished - 2012 Feb 1

Fingerprint

Platinum
Non-Small Cell Lung Carcinoma
Drug Therapy
Disease-Free Survival
Copper
Survival
copper transporter 1
Antineoplastic Agents
Paraffin
Neoplasms
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

@article{b0b48aa1cc5044bfa2850bc2259365a0,
title = "Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy",
abstract = "Background: Recent studies have shown that human copper transporter 1 (hCtr1), the major copper influx transporter, is involved in the transport of platinum-based antitumor agents. We investigated the predictive and prognostic values of hCtr1, and copper efflux transporters ATP7A and ATP7B, in patients with locally advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-based chemotherapy. Methods: From 2004 to 2009, we identified 54 consecutive stage III NSCLC patients who underwent first-line platinum-based doublet chemotherapy. Immunohistochemical studies of hCtr1, ATP7A and ATP7B on the paraffin-embedded pre-treatment tumor samples were performed and correlated with chemotherapy response and survival. Results: Overexpression of hCtr1, ATP7A and ATP7B were observed in 68{\%}, 48{\%} and 74{\%} of the participants, respectively. hCtr1 overexpression was associated with better chemotherapy responses (P< 0.01); whereas ATP7A and ATP7B were not. Patients with hCtr1 overexpressing tumors had better progression-free survival (PFS) and overall survival (OS) (P= 0.01 and 0.047, respectively). In multivariate analyses for chemotherapy response and PFS, only hCtr1 overexpression emerged as a favorable independent predictive and prognostic factor (all P< 0.01). Conclusion: This is the first report to state that hCtr1 is not only an independent predictor of platinum-based chemotherapy response but also a prognostic factor in stage III NSCLC.",
author = "Chen, {Helen H.W} and Yan, {Jiang Jou} and Chen, {Wen Chung} and Kuo, {Macus Tien} and Yu-Hsuan Lai and Wu-Wei Lai and Hsiao-Sheng Liu and Wu-Chou Su",
year = "2012",
month = "2",
day = "1",
doi = "10.1016/j.lungcan.2011.06.011",
language = "English",
volume = "75",
pages = "228--234",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. / Chen, Helen H.W; Yan, Jiang Jou; Chen, Wen Chung; Kuo, Macus Tien; Lai, Yu-Hsuan; Lai, Wu-Wei; Liu, Hsiao-Sheng; Su, Wu-Chou.

In: Lung Cancer, Vol. 75, No. 2, 01.02.2012, p. 228-234.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy

AU - Chen, Helen H.W

AU - Yan, Jiang Jou

AU - Chen, Wen Chung

AU - Kuo, Macus Tien

AU - Lai, Yu-Hsuan

AU - Lai, Wu-Wei

AU - Liu, Hsiao-Sheng

AU - Su, Wu-Chou

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Background: Recent studies have shown that human copper transporter 1 (hCtr1), the major copper influx transporter, is involved in the transport of platinum-based antitumor agents. We investigated the predictive and prognostic values of hCtr1, and copper efflux transporters ATP7A and ATP7B, in patients with locally advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-based chemotherapy. Methods: From 2004 to 2009, we identified 54 consecutive stage III NSCLC patients who underwent first-line platinum-based doublet chemotherapy. Immunohistochemical studies of hCtr1, ATP7A and ATP7B on the paraffin-embedded pre-treatment tumor samples were performed and correlated with chemotherapy response and survival. Results: Overexpression of hCtr1, ATP7A and ATP7B were observed in 68%, 48% and 74% of the participants, respectively. hCtr1 overexpression was associated with better chemotherapy responses (P< 0.01); whereas ATP7A and ATP7B were not. Patients with hCtr1 overexpressing tumors had better progression-free survival (PFS) and overall survival (OS) (P= 0.01 and 0.047, respectively). In multivariate analyses for chemotherapy response and PFS, only hCtr1 overexpression emerged as a favorable independent predictive and prognostic factor (all P< 0.01). Conclusion: This is the first report to state that hCtr1 is not only an independent predictor of platinum-based chemotherapy response but also a prognostic factor in stage III NSCLC.

AB - Background: Recent studies have shown that human copper transporter 1 (hCtr1), the major copper influx transporter, is involved in the transport of platinum-based antitumor agents. We investigated the predictive and prognostic values of hCtr1, and copper efflux transporters ATP7A and ATP7B, in patients with locally advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-based chemotherapy. Methods: From 2004 to 2009, we identified 54 consecutive stage III NSCLC patients who underwent first-line platinum-based doublet chemotherapy. Immunohistochemical studies of hCtr1, ATP7A and ATP7B on the paraffin-embedded pre-treatment tumor samples were performed and correlated with chemotherapy response and survival. Results: Overexpression of hCtr1, ATP7A and ATP7B were observed in 68%, 48% and 74% of the participants, respectively. hCtr1 overexpression was associated with better chemotherapy responses (P< 0.01); whereas ATP7A and ATP7B were not. Patients with hCtr1 overexpressing tumors had better progression-free survival (PFS) and overall survival (OS) (P= 0.01 and 0.047, respectively). In multivariate analyses for chemotherapy response and PFS, only hCtr1 overexpression emerged as a favorable independent predictive and prognostic factor (all P< 0.01). Conclusion: This is the first report to state that hCtr1 is not only an independent predictor of platinum-based chemotherapy response but also a prognostic factor in stage III NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=84855418559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855418559&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2011.06.011

DO - 10.1016/j.lungcan.2011.06.011

M3 - Article

C2 - 21788094

AN - SCOPUS:84855418559

VL - 75

SP - 228

EP - 234

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -